MCID: AND014
MIFTS: 39

Androgenic Alopecia

Categories: Skin diseases

Aliases & Classifications for Androgenic Alopecia

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 12 14
Androgenetic Alopecia 12 69
Alopecia Androgenetica, Male Pattern Baldness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050801
ICD10 32 L64
UMLS 69 C0162311

Summaries for Androgenic Alopecia

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and alopecia. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Coregulation of Androgen receptor activity and Regulation of Androgen receptor activity. The drugs Finasteride and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include testes, prostate and skin.

Related Diseases for Androgenic Alopecia

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 32.1 AR CYP19A1 SHBG
2 alopecia 30.5 AR EDA2R HR SHBG
3 prostatic hyperplasia, benign 30.0 AR CYP19A1 KLK3
4 polycystic ovary syndrome 29.9 CYP19A1 PRL SHBG
5 hyperandrogenism 29.7 CYP19A1 PRL SHBG
6 47, xxy 10.4 AR SHBG
7 postmenopausal atrophic vaginitis 10.4 AR SHBG
8 hermaphroditism 10.4 AR SHBG
9 nodular prostate 10.4 AR KLK3
10 prostatic acinar adenocarcinoma 10.3 AR KLK3
11 hypoactive sexual desire disorder 10.3 CYP19A1 SHBG
12 withdrawal disorder 10.3 AR KLK3
13 transsexualism 10.3 AR CYP19A1
14 gender identity disorder 10.3 AR CYP19A1
15 androgen insensitivity syndrome 10.3 AR SHBG
16 premenstrual tension 10.3 PRL SHBG
17 estrogen excess 10.3 CYP19A1 SHBG
18 cystitis cystica 10.3 AR KLK3
19 oligospermia 10.2 AR PRL
20 suppression of tumorigenicity 12 10.2 AR KLK3
21 mammographic density 10.2 CYP19A1 PRL
22 male reproductive organ cancer 10.2 AR KLK3 SHBG
23 androgen insensitivity, partial 10.2 AR CYP19A1 SHBG
24 pseudohermaphroditism 10.2 AR CYP19A1
25 complete androgen insensitivity syndrome 10.2 AR CYP19A1 SHBG
26 male reproductive system disease 10.2 AR KLK3
27 sexual disorder 10.2 KLK3 PRL SHBG
28 impotence 10.1 KLK3 PRL SHBG
29 breast disease 10.1 KLK3 PRL SHBG
30 cryptorchidism, unilateral or bilateral 10.1 AR CYP19A1 SHBG
31 prostatic hypertrophy 10.1 AR CYP19A1 KLK3
32 prostate disease 10.1 AR CYP19A1 KLK3
33 varicocele 10.1 PRL SHBG
34 anovulation 10.1 CYP19A1 PRL SHBG
35 female reproductive system disease 10.1 CYP19A1 PRL SHBG
36 mccune-albright syndrome 10.1 CYP19A1 PRL
37 premature ovarian failure 1 10.1 CYP19A1 PRL SHBG
38 gonadal disease 10.1 AR SHBG
39 ovarian disease 10.1 CYP19A1 PRL SHBG
40 prostatitis 10.0
41 pedophilia 10.0 LPP PRL
42 prostatic adenoma 9.9 AR KLK3 PRL SHBG
43 sex differentiation disease 9.9 AR CYP19A1 PRL SHBG
44 paraphilia disorder 9.9 LPP PRL
45 amenorrhea 9.9 PRL SHBG
46 ige responsiveness, atopic 9.7
47 prostate cancer 9.7
48 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
49 mungan syndrome 9.7
50 telogen effluvium 9.7

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia

Symptoms & Phenotypes for Androgenic Alopecia

Drugs & Therapeutics for Androgenic Alopecia

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
2
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 38304-91-5 4201
3 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
4 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
6 Hormones Phase 4,Phase 3,Phase 1,Phase 2
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
8 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
9 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2
10
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 6918296 152945
11 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
12
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
13
Acetylcholine Approved Phase 2 51-84-3 187
14
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
15
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
16
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54670067 5785
17
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
18 HIV Protease Inhibitors Phase 2
19
protease inhibitors Phase 2
20 Proteasome Inhibitors Phase 2
21 Adjuvants, Immunologic Phase 2
22 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
23 Anti-Infective Agents Phase 2
24 Antiviral Agents Phase 2
25 Protective Agents Phase 2,Phase 1
26 Radiation-Protective Agents Phase 2
27 Anti-Asthmatic Agents Phase 1, Phase 2
28 Antioxidants Phase 1, Phase 2
29 Autonomic Agents Phase 1, Phase 2
30 Bronchodilator Agents Phase 1, Phase 2
31 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
32 Neurotransmitter Agents Phase 1, Phase 2
33 Peripheral Nervous System Agents Phase 1, Phase 2
34 Respiratory System Agents Phase 1, Phase 2
35 Mitogens Phase 1, Phase 2
36 Androgens Phase 2,Phase 1
37 abobotulinumtoxinA Phase 2
38 Botulinum Toxins Phase 2
39 Botulinum Toxins, Type A Phase 2
40 Cholinergic Agents Phase 2
41 onabotulinumtoxinA Phase 2
42 Ophthalmic Solutions Phase 2
43 Anticonvulsants Phase 2
44 Antimanic Agents Phase 2
45 Central Nervous System Depressants Phase 2
46 GABA Agents Phase 2
47 Psychotropic Drugs Phase 2
48 Tranquilizing Agents Phase 2
49
Ethanol Approved Phase 1 64-17-5 702
50
Methyltestosterone Approved Phase 1 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 104)

# Name Status NCT ID Phase Drugs
1 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
2 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
3 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
4 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
5 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
6 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
7 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
8 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
9 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
10 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
11 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
12 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
13 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
14 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
15 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Active, not recruiting NCT03004469 Phase 3 P-3074;Finasteride;Vehicle
16 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
17 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
18 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
19 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
20 Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
21 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
22 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
23 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
24 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
25 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
26 A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
27 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
28 Treatment of Male Pattern Baldness With Botulinum Toxin Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
29 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
30 Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Completed NCT02150187 Phase 2
31 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
32 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
33 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
34 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
35 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) Completed NCT01451125 Phase 2
36 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
37 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) Completed NCT01669746 Phase 2
38 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) Completed NCT01451190 Phase 2
39 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) Completed NCT01451177 Phase 2
40 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) Completed NCT01451151 Phase 2
41 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) Completed NCT01451138 Phase 2
42 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) Completed NCT01451112 Phase 2
43 A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
44 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) Completed NCT01451073 Phase 2
45 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) Completed NCT01451047 Phase 2
46 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
47 The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Completed NCT01548066 Phase 2 Valproic Acid;Control placebo
48 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
49 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss Completed NCT01900041 Phase 2 Pantovigar;Minoxidil 2% only
50 AGA Biocellular Stem/Stromal Hair Regenerative Study Recruiting NCT02849470 Phase 1, Phase 2

Search NIH Clinical Center for Androgenic Alopecia

Genetic Tests for Androgenic Alopecia

Anatomical Context for Androgenic Alopecia

MalaCards organs/tissues related to Androgenic Alopecia:

38
Testes, Prostate, Skin, Bone, Ovary, Brain

Publications for Androgenic Alopecia

Articles related to Androgenic Alopecia:

(show top 50) (show all 491)
# Title Authors Year
1
Low-level laser therapy for the treatment of androgenic alopecia: a review. ( 29270707 )
2018
2
Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. ( 29101437 )
2018
3
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. ( 29443105 )
2018
4
Androgenic alopecia in a postmenopausal Sicilian baroness. ( 29103134 )
2018
5
A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. ( 29440850 )
2018
6
A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. ( 29407002 )
2018
7
Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. ( 29227728 )
2017
8
Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. ( 28222425 )
2017
9
Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report. ( 29090364 )
2017
10
Injections of platelet-rich plasma for androgenic alopecia: A systematic review. ( 28676455 )
2017
11
Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. ( 28932074 )
2017
12
Comparison of the effects of 665 nm low level diode Laser Hat versus and a combination of 665 nm and 808nm low level diode Laser Scanner of hair growth in androgenic alopecia. ( 28513251 )
2017
13
Systematic review of low-level laser therapy for adult androgenic alopecia. ( 29286826 )
2017
14
A Spilt Head Study of Efficacy of Placebo versus Platelet-rich Plasma Injections in the Treatment of Androgenic Alopecia. ( 28852294 )
2017
15
Androgenic alopecia: an entity to consider in adolescence. ( 28754756 )
2017
16
A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. ( 29403190 )
2017
17
Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution? ( 29224248 )
2017
18
Conventional and novel stem cell based therapies for androgenic alopecia. ( 28979149 )
2017
19
Psychosocial Impairment as a Possible Cause of Sexual Dysfunction among Young Men with Mild Androgenetic Alopecia: A Cross-sectional Crowdsourcing Web-based Study. ( 27149130 )
2016
20
A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. ( 27661430 )
2016
21
Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. ( 27152474 )
2016
22
Efficacy of Activated 3X Platelet-Rich Plasma in the Treatment of Androgenic Alopecia. ( 28296871 )
2016
23
Identification of a new plant extract for androgenic alopecia treatment using a non-radioactive human hair dermal papilla cell-based assay. ( 26796631 )
2016
24
Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. ( 27942367 )
2016
25
Commentary on A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. ( 27661431 )
2016
26
Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels. ( 27155830 )
2016
27
A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. ( 27631460 )
2016
28
Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( 27050695 )
2016
29
Platelet-Rich Plasma Growth Factor Concentrated Spray (KeratogrowAr) as a Potential Treatment for Androgenic Alopecia. ( 28296870 )
2016
30
Assessment of vitamin D receptors in alopecia areata and androgenetic alopecia. ( 27151518 )
2016
31
Are 2D:4D finger-length ratios an indicator of androgenetic alopecia in males? ( 27192513 )
2016
32
Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. ( 27988928 )
2016
33
The role of oxidative stress in early-onset androgenetic alopecia. ( 27987270 )
2016
34
Metabolic syndrome in androgenic alopecia. ( 26858057 )
2016
35
Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. ( 28024997 )
2016
36
Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? ( 26990657 )
2016
37
Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( 27050694 )
2016
38
Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. ( 27553744 )
2016
39
Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. ( 27046152 )
2016
40
Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? ( 27489744 )
2016
41
Platelet-Rich Plasma in Androgenic Alopecia: Indications, Technique, and Potential Benefits. ( 27918883 )
2016
42
Differential Expression between Human Dermal Papilla Cells from Balding and Non-Balding Scalps Reveals New Candidate Genes for Androgenetic Alopecia. ( 27060448 )
2016
43
Metabolic syndrome in androgenic alopecia. ( 27279298 )
2016
44
Editorial - Mesenchymal Stem Cells in Androgenic Alopecia: Hair Loss Regeneration. ( 28296869 )
2016
45
Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. ( 25903108 )
2015
46
Characteristics of nonbalding scalp zones of androgenetic alopecia in East Asians. ( 25532463 )
2015
47
Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. ( 25842469 )
2015
48
Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men. ( 26380503 )
2015
49
Trichoscopic findings of androgenetic alopecia and their association with disease severity. ( 25810236 )
2015
50
The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. ( 25781062 )
2015

Variations for Androgenic Alopecia

Expression for Androgenic Alopecia

Search GEO for disease gene expression data for Androgenic Alopecia.

Pathways for Androgenic Alopecia

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.08 AR KLK3
2 10.96 AR KLK3
3
Show member pathways
10.82 AR KLK3
4 10.61 AR CYP19A1
5 9.88 AR SHBG

GO Terms for Androgenic Alopecia

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.13 EFNA3 KLK3 PRL
2 prostate gland growth GO:0060736 8.62 AR CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 AR SHBG
2 androgen binding GO:0005497 8.62 AR SHBG

Sources for Androgenic Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....